Subscribe To
Cassava sciences starts late-stage simufilam study in alzheimer's patients
Cassava Sciences Inc (NASDAQ: SAVA) initiated an initial Phase 3 efficacy study of simufilam, an inv...
October 6, 2021, 12:31 pm
Cassava sciences starts late-stage simufilam study in alzheimer's patients
Cassava Sciences Inc (NASDAQ: SAVA) initiated an initial Phase 3 efficacy study of simufilam, an inv...
October 6, 2021, 12:31 pm
Cassava sciences starts late-stage simufilam study in alzheimer's patients
Cassava Sciences Inc (NASDAQ: SAVA) initiated an initial Phase 3 efficacy study of simufilam, an inv...
October 6, 2021, 12:31 pm
Microchip and acacia collaborate to enable market transition to 400g pluggable coherent optics for data center routing, switching and metro otn platforms
Solutions enable encrypted 100/400 GbE, FlexE and Flexible OTN interfaces for 400ZR, Open ZR+ and Open ROADM applications...
October 6, 2021, 8:09 am
Microchip and acacia collaborate to enable market transition to 400g pluggable coherent optics for data center routing, switching and metro otn platforms
Solutions enable encrypted 100/400 GbE, FlexE and Flexible OTN interfaces for 400ZR, Open ZR+ and Open ROADM applications...
October 6, 2021, 8:09 am
Microchip and acacia collaborate to enable market transition to 400g pluggable coherent optics for data center routing, switching and metro otn platforms
Solutions enable encrypted 100/400 GbE, FlexE and Flexible OTN interfaces for 400ZR, Open ZR+ and Open ROADM applications...
October 6, 2021, 8:09 am
Genentech to present new data on ocrevus (ocrelizumab) in multiple sclerosis and enspryng (satralizumab-mwge) in neuromyelitis optica spectrum disorder at ectrims 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® ...
October 5, 2021, 1:00 am
Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...
October 5, 2021, 1:00 am
Genentech to present new data on ocrevus (ocrelizumab) in multiple sclerosis and enspryng (satralizumab-mwge) in neuromyelitis optica spectrum disorder at ectrims 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® ...
October 5, 2021, 1:00 am
Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...
October 5, 2021, 1:00 am
Genentech to present new data on ocrevus (ocrelizumab) in multiple sclerosis and enspryng (satralizumab-mwge) in neuromyelitis optica spectrum disorder at ectrims 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® ...
October 5, 2021, 1:00 am
Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...
October 5, 2021, 1:00 am
Genentech to present new data on ocrevus (ocrelizumab) in multiple sclerosis and enspryng (satralizumab-mwge) in neuromyelitis optica spectrum disorder at ectrims 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® ...
October 5, 2021, 1:00 am
Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...
October 5, 2021, 1:00 am
Genentech to present new data on ocrevus (ocrelizumab) in multiple sclerosis and enspryng (satralizumab-mwge) in neuromyelitis optica spectrum disorder at ectrims 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® ...
October 5, 2021, 1:00 am
Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...
October 5, 2021, 1:00 am
Genentech to present new data on ocrevus (ocrelizumab) in multiple sclerosis and enspryng (satralizumab-mwge) in neuromyelitis optica spectrum disorder at ectrims 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® ...
October 5, 2021, 1:00 am
Genentech to present new data on ocrevus (ocrelizumab) in multiple sclerosis and enspryng (satralizumab-mwge) in neuromyelitis optica spectrum disorder at ectrims 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® ...
October 5, 2021, 1:00 am
Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...
October 5, 2021, 1:00 am
Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...
October 5, 2021, 1:00 am